Ultrasound-triggered herceptin liposomes for breast cancer therapy.

Amal Elamir, Saniha Ajith, Nour Al Sawaftah, Waad Abuwatfa, Debasmita Mukhopadhyay, Vinod Paul, Mohammad H Al-Sayah, Nahid Awad, Ghaleb A Husseini

Scientific reports 2021 Apr 06

filter terms:

The functionalization of liposomes with monoclonal antibodies is a potential strategy to increase the specificity of liposomes and reduce the side-effects associated with chemotherapeutic agents. The active targeting of the Human Epidermal growth factor Receptor 2 (HER2), which is overexpressed in HER2 positive breast cancer cells, can be achieved by coating liposomes with an anti-HER2 monoclonal antibody. In this study, we synthesized calcein and Doxorubicin-loaded immunoliposomes functionalized with the monoclonal antibody Trastuzumab (TRA). Both liposomes were characterized for their size, phospholipid content and antibody conjugation. Exposing the liposomes to low-frequency ultrasound (LFUS) triggered drug release which increased with the increase in power density. Trastuzumab conjugation resulted in enhancing the sensitivity of the liposomes to LFUS. Compared to the control liposomes, TRA-liposomes showed higher cellular toxicity and higher drug uptake by the HER2 + cell line (SKBR3) which was further improved following sonication with LFUS. Combining immunoliposomes with LFUS is a promising technique in the field of targeted drug delivery that can enhance efficiency and reduce the cytotoxicity of antineoplastic drugs.

Citation

Amal Elamir, Saniha Ajith, Nour Al Sawaftah, Waad Abuwatfa, Debasmita Mukhopadhyay, Vinod Paul, Mohammad H Al-Sayah, Nahid Awad, Ghaleb A Husseini. Ultrasound-triggered herceptin liposomes for breast cancer therapy. Scientific reports. 2021 Apr 06;11(1):7545